Production of a biosimilar version of aflibercept to improve VEGF blocker cytotoxicity on endothelial cells.

Ramezani, Amin; Zareinejad, Mohammadrasul; Mahmoudi Maymand, Elham; Kaviani, Elina; Ghaderi, Abbas

Ramezani, Amin; Zareinejad, Mohammadrasul; Mahmoudi Maymand, Elham; Kaviani, Elina; Ghaderi, Abbas.

Afiliação

Ramezani A; Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.
Zareinejad M; School of Medicine, Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran.
Mahmoudi Maymand E; School of Medicine, Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran.
Kaviani E; School of Medicine, Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran.
Ghaderi A; Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.

Growth Factors ; 41(3): 140-151, 2023 08.

Article em En | MEDLINE | ID: mdl-37377438

Assuntos

Medicamentos Biossimilares; Fator A de Crescimento do Endotélio Vascular; Fator A de Crescimento do Endotélio Vascular/metabolismo; Inibidores da Angiogênese/farmacologia; Inibidores da Angiogênese/uso terapêutico; Células Endoteliais/metabolismo; Medicamentos Biossimilares/farmacologia; Proteínas Recombinantes de Fusão/genética; Proteínas Recombinantes de Fusão/farmacologia; Sorafenibe/farmacologia

Palavras-chave

Aflibercept; VEGF-Trap fusion protein; everolimus; lenvatinib; sorafenib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fator A de Crescimento do Endotélio Vascular / Medicamentos Biossimilares Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google